HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Sichuan Baili Pharmaceutical Co., Ltd. Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Sichuan Baili Pharmaceutical Co., Ltd. Intelligence Report

Generated from 2 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Aug 5, 2026

Confidence

Moderate Confidence · 66%

Evidence

12 items

Sources

11

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Sichuan Baili Pharmaceutical Co., Ltd. maintains an active intelligence profile across Oncology, NSCLC, Non-small Cell Lung Cancer. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 66% across 2 tracked sources. Highest-priority development: Verified Clinical Benefit | Cancer Accelerated Approvals. Regulatory precedent. Why this matters: sets a approval precedent in the same sub-indication (lung cancer) as Sichuan Baili Pharmaceutical Co., Ltd..

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    Verified Clinical Benefit | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    Cancer Clinical Trial Eligibility Criteria: Performance Status

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Cancer Clinical Trial Eligibility Criteria: Laboratory Values

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    Other | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Ongoing | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Verified Clinical Benefit | Cancer Accelerated Approvals

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 41 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Cancer Clinical Trial Eligibility Criteria: Performance Status

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Cancer Clinical Trial Eligibility Criteria: Laboratory Values

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Other | Cancer Accelerated Approvals

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Ongoing | Cancer Accelerated Approvals

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Verified Clinical Benefit | Cancer Accelerated Approvals

    Low Confidence · 54%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Phase II/III Trial of BL-B01D1 with Osimertinib in EGFR-mutant NSCLC Initiated

    Oncology · NSCLC

  • Phase II Study of BL-B01D1 with PD-1 Antibody in Advanced Lung Cancer and Other Tumors

    Oncology · Non-small Cell Lung Cancer

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.